Bristol-myers Squibb Compnay

Bayer Pharmaceuticals Corporation

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Qian Zhao

Paul Michael Scola

Li-Qiang Sun

Eric P Gillis

Chengzhi Zhang

Jacques P Dumas

Tao Wang

Zhongxing Zhang

Kandhasamy Sarkunam

Martin F Hentemann

Nicholas A Meanwell

Roger Astbury Smith

Michael A Poss

Eric Mull

Gaetan H Ladouceur

Barton W Phillips

Michael Matthew Miller

Jianmei Fan

David R Langley

Annapurna Pendri

Zhiwei Yin

Wendy Lee

Claudio Mapelli

Benjamin Jones

Jason A Duquette

Samuel Gerritz

Ramkumar Rajamani

Kap-Sun Yeung

Kenneth M Boy

Jason T Goodrich

Katharine A Grant-Young

Alan Xiangdong Wang

Stanley V D'Andrea

Kevin W Gillman

Zheng Liu

Mario Lobell

Chetan Padmakar Darne

Yunhui Zhang

Michael S Bowsher

Martin Patrick Allen

Pulicharla Nagalakshmi

Kishore V Renduchintala

Qingming Zhu

Sharad Verma

Dongping Fan

Rico C Lavoie

Zhi Chen

Guo Li

Weixu Zhai

Ling Li

Scott Wilhelm

Maude A Poirier

Michael J Burke

Sheldon Hiebert

Pvk Suresh Babu

Georgiy Bondar

Lyndon A M Cornelius

Jason S Newcom

Juliang Zhu

Qingjie Liu

Philip Coish

Yingfu Li

Daniel J Tenney

Kristen M Allegue

Barbara Zhizhen Zheng

Nishith Sanghvi

P V K Suresh Babu

Kanwar Sidhu

M Nicholas Meanwell

Suresh PVK Babu

Gaetan Ladouceur

Jason Newcom

Chetan P Darne

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions

Immunomodulators

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Macrocyclic compounds as HCV entry inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed. 

The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

Growing community of inventors

Wallingford, CT, United States of America

Qian Zhao